Last reviewed · How we verify
GSK malaria vaccine 257049 Vaccine
GSK malaria vaccine 257049 Vaccine is a Biologic drug developed by GlaxoSmithKline. It is currently in Phase 2 development for Prevention of malaria in individuals 6 weeks of age and older. Also known as: RTS, S/AS01E vaccine.
This vaccine induces an immune response against Plasmodium falciparum, the parasite responsible for malaria.
This vaccine induces an immune response against Plasmodium falciparum, the parasite responsible for malaria. Used for Prevention of malaria in individuals 6 weeks of age and older.
At a glance
| Generic name | GSK malaria vaccine 257049 Vaccine |
|---|---|
| Also known as | RTS, S/AS01E vaccine |
| Sponsor | GlaxoSmithKline |
| Modality | Biologic |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 2 |
Mechanism of action
The vaccine works by stimulating the body's immune system to recognize and attack the parasite, thereby preventing malaria infection. It achieves this through a combination of antigens and adjuvants that mimic the natural infection process, allowing the immune system to develop a targeted response.
Approved indications
- Prevention of malaria in individuals 6 weeks of age and older
Common side effects
- Injection site pain
- Fatigue
- Headache
Key clinical trials
- Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants (PHASE2)
- A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Candidate Vaccines RTS,S/AS02D (0.5 mL Dose) and RTS,S/AS02A (0.25 mL Dose) Administered IM According to a 0, 1, 2 Month Vaccination Schedule in Children Aged 3 to 5 Years Living in a Malaria-endemic Region of Mozambique. (PHASE1)
- An Extension to Study MALARIA-055 PRI (NCT00866619) to Evaluate the Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine in Infants and Children in Africa (PHASE3)
- Efficacy of GSK Biologicals' Candidate Malaria Vaccine 257049 Against Malaria Disease in Infants and Children in Africa (PHASE3)
- Study to Evaluate Immunogenicity of the Hepatitis B Antigen of the GSK Biologicals' Candidate Malaria Vaccine (257049) (PHASE3)
- Efficacy, Safety and Immunogenicity Study of GlaxoSmithKline(GSK) Biologicals' Candidate Malaria Vaccine 257049 in the Sporozoite Challenge Model in Healthy Malaria-naïve Adults (PHASE2)
- Safety, Immunogenicity and Efficacy Against of a Combined Malaria Vaccine in Healthy Malaria-naïve Adults (PHASE2)
- Safety and Immunogenicity of GSK Biologicals' Investigational Malaria Vaccine in HIV Infected Infants and Children (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK malaria vaccine 257049 Vaccine CI brief — competitive landscape report
- GSK malaria vaccine 257049 Vaccine updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about GSK malaria vaccine 257049 Vaccine
What is GSK malaria vaccine 257049 Vaccine?
How does GSK malaria vaccine 257049 Vaccine work?
What is GSK malaria vaccine 257049 Vaccine used for?
Who makes GSK malaria vaccine 257049 Vaccine?
Is GSK malaria vaccine 257049 Vaccine also known as anything else?
What development phase is GSK malaria vaccine 257049 Vaccine in?
What are the side effects of GSK malaria vaccine 257049 Vaccine?
Related
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Infectious Diseases
- Indication: Drugs for Prevention of malaria in individuals 6 weeks of age and older
- Also known as: RTS, S/AS01E vaccine
- Compare: GSK malaria vaccine 257049 Vaccine vs similar drugs
- Pricing: GSK malaria vaccine 257049 Vaccine cost, discount & access